Search

Your search keyword '"Ganti, Apar Kishor"' showing total 682 results
Start Over Author "Ganti, Apar Kishor"
682 results on '"Ganti, Apar Kishor"'

117. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study

Author

Ernani, Vinicius, primary, Jahan, Rahat, additional, Smith, Lynette M., additional, Marr, Alissa S., additional, Kimbrough, Sarah E., additional, Kos, Mary E., additional, Tijerina, Jolene, additional, Pivovar, Shannon, additional, Lakshmanan, Imayavaramban, additional, Ketcham, Marsha, additional, Rauth, Sanchita, additional, Mallya, Kavita, additional, Nasser, Mohd W, additional, Jain, Maneesh, additional, Kessinger, Anne, additional, Batra, Surinder K., additional, and Ganti, Apar Kishor, additional

Published
2020
Full Text
View/download PDF

119. Local Clinical Trials: The Need of the Hour to Improve Global Cancer Care.

Author

Ganti, Apar Kishor

Subjects
*CLINICAL trials, *CANCER treatment, *CENTRAL nervous system cancer, *CLINICAL trials monitoring, *NON-small-cell lung carcinoma, *SMALL cell lung cancer
Abstract

Clinical trials play a crucial role in advancing cancer care and improving patient outcomes. However, the proportion of cancer patients enrolled in clinical trials is low, even in advanced countries. Global studies tend to enroll patients from countries with robust clinical trial infrastructure, potentially leaving out patients from other regions. There are significant differences in the tolerability and efficacy of anticancer drugs between different populations, highlighting the need for research in countries where specific cancers are more prevalent. Lower- and middle-income countries bear a significant burden of cancer cases and deaths, but the benefits of research in developed countries are not reaching them. Conducting local research in these countries is essential to ensure that patients receive treatments relevant to their specific populations. However, there are challenges such as limited research training and time constraints for clinicians in these settings. Governments should facilitate clinical trials by establishing research infrastructure, providing training programs, and reducing barriers to research. This can lead to regional collaborations and improve the quality of cancer care worldwide, reducing disparities and alleviating the global cancer burden. [Extracted from the article]

Published
2024
Full Text
View/download PDF

122. Letters to the editor

Author

Khaliq, Amir A., Ganti, Apar Kishor, Smego, Raymond A., Jr., Parekh, Vikas I., Kulaga, Mark, OʼMahony, Stephen, Charney, Pamela, and Mazur, Eric

Published
2005
Full Text
View/download PDF

128. Patient-Defined Treatment Success: Perspectives of Patients With Advanced-Stage Lung Cancer

Author

Islam, K.M., primary, Deviany, Poppy E., additional, Anggondowati, Trisari, additional, Ryan, June E., additional, Fetrick, Ann, additional, Bagenda, Danstan, additional, Copur, Mehmet S., additional, Tolentino, Addison, additional, Vaziri, Irfan, additional, McKean, Heidi A., additional, Dunder, Steven, additional, Gray, Jhanelle E., additional, Huang, Chao M.D., additional, and Ganti, Apar Kishor, additional

Published
2019
Full Text
View/download PDF

129. Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081.

Author

Yan, Melissa, primary, Durm, Greg Andrew, additional, Mamdani, Hirva, additional, Ganti, Apar Kishor, additional, Hrinczenko, Borys, additional, Jabbour, Salma K., additional, Feldman, Lawrence Eric, additional, Kloecker, Goetz H., additional, Leal, Ticiana, additional, Almokadem, Salah, additional, Naidoo, Jarushka, additional, Fujioka, Naomi, additional, and Hanna, Nasser H., additional

Published
2019
Full Text
View/download PDF

138. Salivary gland cancers: biology and systemic therapy

Author

Goyal, Gaurav, Mehdi, Syed A., and Ganti, Apar Kishor

Subjects
Gene mutations -- Health aspects, Translocation (Genetics) -- Health aspects, Mouth cancer -- Genetic aspects -- Care and treatment, Salivary glands -- Diseases, Health
Abstract

Salivary gland tumors are a relatively rare and heterogeneous group of tumors with variable pathologic and phenotypic characteristics. The lack of clinical outcomes data and randomized controlled trials pertaining to them makes it difficult to formulate definitive treatment protocols that could help with making decisions regarding choice of therapy. Most studies involving systemic chemotherapy have not shown promising patient outcome results. With recent advances in molecular technology, however, it is now possible to identify specific genetic alterations and biomarkers as possible targets for therapeutic purposes. For example, in mucoepidermoid carcinomas, one of the most common types of malignant salivary gland tumors, a commonly seen genetic translocation [t(11;19)(q21;p13), which involves the CRTC1 and MAML2 genes] has been found to be associated with improved survival, making it a possible prognostic marker. Also, this translocation gives rise to a fusion protein that appears to render tumors highly sensitive to epidermal growth factor receptor (EGFR) inhibition. However, the results of phase II trials of EGFR inhibitors--as well as other targeted agents--in salivary gland tumors have been disappointing: there has been some disease stabilization but no objective responses. There remains a need for well-designed prospective clinical studies to improve management of these tumors., Introduction Salivary gland cancers are a rare, heterogeneous group of tumors that comprise less than 5% of head and neck cancers and about 0.5% of all malignancies. [1] They vary [...]

Published
2015

139. The Meaning of Care for Veterans

Author

Cohen, Marlene Z., primary, Struwe, Leeza, additional, Fletcher, Barbara Swore, additional, Kingston, Eileen, additional, Bockman, Tammy, additional, Shimerdla, Deborah, additional, Harrington, Richard, additional, Robino-West, Sharon, additional, and Ganti, Apar Kishor, additional

Published
2018
Full Text
View/download PDF

141. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018

Author

Kalemkerian, Gregory P., primary, Loo, Billy W., additional, Akerley, Wallace, additional, Attia, Albert, additional, Bassetti, Michael, additional, Boumber, Yanis, additional, Decker, Roy, additional, Dobelbower, M. Chris, additional, Dowlati, Afshin, additional, Downey, Robert J., additional, Florsheim, Charles, additional, Ganti, Apar Kishor P., additional, Grecula, John C., additional, Gubens, Matthew A., additional, Hann, Christine L., additional, Hayman, James A., additional, Heist, Rebecca Suk, additional, Koczywas, Marianna, additional, Merritt, Robert E., additional, Mohindra, Nisha, additional, Molina, Julian, additional, Moran, Cesar A., additional, Morgensztern, Daniel, additional, Pokharel, Saraswati, additional, Portnoy, David C., additional, Rhodes, Deborah, additional, Rusthoven, Chad, additional, Sands, Jacob, additional, Santana-Davila, Rafael, additional, Williams, Charles C., additional, Hoffmann, Karin G., additional, and Hughes, Miranda, additional

Published
2018
Full Text
View/download PDF

150. Amiodarone-induced thyrotoxicosis presenting as hypokalemic periodic paralysis. (Case Reports)

Author

Laroia, Sandeep T., Zaw, Khin M., Ganti, Apar Kishor, Newman, William, and Akinwande, Akindolapo O.

Subjects
Thyroid diseases -- Diagnosis -- Care and treatment, Health, Diagnosis, Care and treatment
Abstract

ABSTRACT: Thyroid disorder is a well-recognized side effect of amiodarone therapy. Thyrotoxicosis is less common than hypothyroidism. Hypokalemic periodic paralysis is one manifestation of thyrotoxicosis, and is more often seen [...]

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results